Brazil's MedTech Maze: A Pure Global Guide to ANVISA's "Cadastro" and "Notificação" for Class I Devices

This episode of LATAM MedTech Insights tackles the common misconceptions surrounding the registration of Class I medical devices in Brazil. We move beyond the outdated term "cadastro" to provide a detailed breakdown of the current "notificação" (notification) pathway managed by ANVISA. Learn why this simplified, faster route to market is often misunderstood by foreign manufacturers. We explore the critical, non-negotiable requirements that are often overlooked. From the strategic importance of selecting the right Brazil Registration Holder (BRH) to the necessity of a complete technical dossier that ANVISA can audit at any time, we cover the essential groundwork. We share a real-world example of a company whose product launch was delayed for months simply because their translated user manual didn't meet specific Brazilian formatting rules, highlighting how a small oversight can lead to significant commercial setbacks. This episode is a must-listen for any MedTech company looking to successfully enter the lucrative Brazilian market. Key Takeaways: * What is the crucial difference between the "cadastro" and the modern "notificação" process? * Why is your choice of a Brazil Registration Holder (BRH) the single most important decision for your market entry strategy? * Does a "simplified notification" mean you don't need a full technical dossier? * What are the specific labeling and language requirements that cause the most customs delays? * How do you determine if your Class I device needs a separate INMETRO certification? * What post-market surveillance responsibilities fall on your BRH? * Why is assuming "low-risk" means "low-compliance" a major financial risk in Brazil? At Pure Global, we specialize in transforming these regulatory hurdles into clear pathways for market success. We offer end-to-end solutions for MedTech and IVD companies, acting as your local representative and ensuring full compliance across Latin America and more than 30 markets worldwide. Let us handle the complexities of ANVISA, so you can focus on growth. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.